Maria Hjorth is proposed to join the board of Monsenso as chairman

Maria Hjorth is proposed to join the board of Monsenso as chairman

Monsenso today announces that the board of Directors proposes Maria Hjorth to be elected for the board at the General Assembly on April 14th, 2021.

Monsenso – a leading provider of digital health solutions for mental health – plans to further strengthen the board by nominating a new professional board member with strong qualifications and competencies to support the company’s growth journey: Maria Hjorth, CEO at VP Securities A/S

Maria Hjorth will replace Jukka Pertola, who – as previously announced – will withdraw from the board of directors in order to comply with good board governance practices by reducing his number of board positions.

The board and the management of Monsenso would like to thank Jukka Pertola for his efforts in supporting the management, the company in general and particularly the listing on Nasdaq First North in 2020.

The new board plans to constitute itself with Maria Hjorth as the Chairman and Jakob Bardram as the Vice Chairman following the ordinary Annual General Meeting on April 14, 2021, where Jukka Pertola is expected to resign as the Chairman.

The nomination of Maria Hjorth follows a change in the board in January, where Peter Høngaard Andensen and Jacob Hahn Michelsen were elected with the aim to strengthen the competences and diversity of the board.

Jukka Pertola commented: ”It is sad to pass on the chairmanship, but I have to do so to comply with demands related to good corporate governance. On the other hand, I am very pleased that with Maria Hjorth and the changes made in January, we have a competent and experienced board that is well positioned to help Monsenso reach the next level. Jacob Hahn Michelsen and Peter Høngaard Andersen brought extensive experience in pharma- and health-related software, medical applications, science and research, pharmaceuticals, neurology, innovation and funding. Maria Hjorth’s experiences from top management, financial businesses, investor relations and M&A is a great supplement to the rest of the board”.

To read the Danish version, click here.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

The EcoWeb project has recruited more than 1600 participants across four countries despite COVID-19

The EcoWeb project has recruited more than 1600 participants across four countries despite COVID-19

Since the EcoWeB project launched MyMoodCoach (an app powered by Monsenso) in November 2020 it has recruited more than 1600 young participants in Belgium, UK, Spain and Germany.

The EcoWeB research study, led by Professor Ed Watkins University of Exeter, seeks to understand what influences mood, how emotions change over time, and which emotional skills increase well-being among youth.

The participants are asked to use MyMoodCoach to monitor their emotions in daily life, while giving them access to “Tools” and “Challenges” to boost their mental health and wellbeing. ‘Tools’ provide the participants with strategies to help them if they feel sad, stressed, anxious or have a problem. ‘Challenges’ help them to learn new skills, develop a positive mindset, improve their confidence and gain insight into their emotions.

The strong pick up of MyMoodCoach reflects a desire among youth to take better care of their mental wellbeing.

“We are very pleased to contribute to this project, as young people have been particularly impacted by COVID-19.” says Thomas Lethenborg, CEO of Monsenso. “Mobile health solutions have proved true value during the pandemic, allowing both clinical practice and important research projects to continue despite lockdowns.”

About the project:

The EcoWeB project is led by Professor Ed Watkins, University of Exeter, and involves 13 different institutions across 8 European nations (the UK, Germany, Belgium, Spain, Greece, the Czech Republic, Denmark, and Switzerland). The project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 754657.

About Monsenso digital health solution:
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com.

Monsenso expands in the Middle East with new million deal with global pharmaceutical company

Monsenso expands in the Middle East with new million deal with global pharmaceutical company

Monsenso has entered a new million agreement with a global pharmaceutical company and hereby expands its activities to six countries in the Middle East. As part of the agreement, Monsenso will provide its solution for patient monitoring and treatment support in the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar and Bahrain.

Monsenso’s solution will be used to support the treatment of depression and schizophrenia. Patients are provided with an app, which is used to collect real-time patient-reported information and to give patients access to information about their disorder between consultations. Therapists gain access to a clinical web portal and can follow their patients remotely and gain valuable information about behavior, medication intake and symptoms and thus be able to provide a data-driven treatment and allow for proactive follow-up.
In addition, the solution supports communication between patients and therapists.

“We are very pleased with this agreement, which contributes to both expanding our geographic market coverage and our business with pharmaceutical companies in line with our growth strategy. ” says Thomas Lethenborg, CEO of Monsenso. “Depression and schizophrenia are among the most costly disorders for society and have major consequences for affected patients and relatives. Therefore, we are proud to be able to contribute to better treatment within these disease areas.”

The project will not affect Monsenso’s previously communicated plans and guidance for the 2020 financial year.

To read the Danish version, click here.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Big Data in treating mental disorders

Big Data in treating mental disorders

Big data in treating mental disorders explains how data is transforming the treatment of mental disorders and the overall life science industry. Monsenso’s mHealth solution shows how technology provides new ways to inform treatment and achieve scalability. This is a blog post written by Mads Frost PhD, Co-founder and Chief Product Officer of Monsenso. 

The challenge with mental health today

According to numerous analyses and forecasts conducted by several international organizations and authorities, mental health today is one of the biggest challenges for society and health budgets. In fact, the World Health Organization (WHO) has predicted that mental disorders will be the greatest health burden for society in the coming years. This emphasizes the need for solutions to remedy this. Presently, technology is the best bet.

An example of the utilisation of technology to help overcome the burden of mental health for society is Monsenso. Monsenso is an innovation leader in mHealth solutions for the treatment of mental disorders. Monsenso helps support the treatment of mental disorders by inspiring and strengthening cooperation between patients and therapists.

Based on continuous research with leading experts in psychiatry, pervasive healthcare and data science, Monsenso has designed an innovative solution that fits into each patient’s life and helps them to better manage their disease as well as increasing the quality and effectiveness of treatment. It has been developed in a user-centred design approach, with patients, clinicians and relatives, to ensure that the solution is easy to apply and fits into the patient’s life and treatment.

The mental x-ray

Through daily self-assessment, clinical questionnaires, and collection of behavioural data from both sensors in modern Smartphone, wearables, and even voice analyses of patients’ voices, Monsenso provides the patient and the therapist with a detailed insight into the user’s mental health state. Through the application of advanced data analysis, indicators such as behavioural patterns, contexts and even forecasting future conditions and risk levels can be demonstrated – all with the purpose of gaining better insight into the patient’s mental health and providing an improved basis for treatment.

Generally, many organizations are fighting to realize mHealth’s full potential. According to a study where clinicians have been asked: “What is your most pressing information technology problem”, the answer that received the highest percentage of responses was, “turning data into action.” [1]

Psychiatry has previously used paper schemes to collect information from patients. However, but current technology provides access to a wide range of information that has not previously been available. This technology can be called the mental x-ray, in that using this technology can be used to see and monitor mental functioning with x-ray like precision and detail. This allows for early interventions and to help patients when they are in need. An example of this at work is the Monsenso based research into using voice analysis as an objective state marker for bipolar disorder . [2]

Paradigm shift in treatment: How do we achieve scalability?

To achieve the benefits of technology, it is necessary to adapt the clinical workflows. Psychiatry has a very traditional form of treatment where the patient meets the therapist and receives face-to-face treatment. The future brings more patients and fewer therapists – how do we scale this?

One possible solution is to optimising treatment is to use monitoring systems. These systems can rapidly identify which patients are in need of help, and which ones are well. In this way, clinicians’ time can be focused on patients who are in need.  Likewise, the systems can be more treatment-supporting, taking over the trivial and automatable tasks of the clinician, allowing them to spend their time on those with the greatest needs – the complex cases that technology cannot help. The last perspective – a paradigm shift in treatment – is to go from a reactive to a proactive approach. The proactive approach comes from gathering more detailed information, to lead to more informed decisions and earlier interventions. More information can help immediately notify both patients and clinicians when things start to go in the wrong direction, and need help to prevent potential hospitalisations. And the patients, who are well, can focus on life and not illness. However, it is important to keep in mind that it is not a trivial task to realise this.

How should we realise the potential of ‘Big Data’

On an overall level, there are a number of points that companies that are active in data-driven health technology should think about to thrive in complex health environments:

  • Find applications and services that bring tangible value to identifiable stakeholders – it must provide meaning and value to end users
  • Think on a global scale
  • Focus on solutions, not technology
  • Identify potential partners to create greater impact and find new value

Most of all, those who come from the outside into the healthcare domain must avoid the trap of seeing technology as something different from healthcare. Its greatest value will be how it integrates with healthcare systems and allows clinicians to provide better care for patients.

In some cases, technology will appear illusory: Personal contact between patient and therapist will always have a place in treatment, but data driven approaches can revolutionise the basis on which treatment is given.

Where are we going?

There are many possibilities that presents itself when exploring data driven approaches. I have  particularly emphasised ‘Context Aware Computing’ as one of the perspectives that are important to pursue. The goal is to use the context of the patients to provide the right intervention, to the right patient, at the right time, at the right place. This is not a trivial task, but extremely important for solutions like Monsenso to really help patients. The present systems are still relatively unintelligent in terms of achieving this, based on the amount of data available. It is difficult to know the context of what the collected data in the system is based on – what experiences and thoughts the patients have.

[1]  Top 5 industry challenges of 2016 By Aubrey Westgate, November 30, 2015  http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/top-5-industry-challenges-2016?page=0,0

[2]  VOICE ANALYSIS AS AN OBJECTIVE STATE MARKER IN BIPOLAR DISORDER. M Faurholt-Jepsen, J Busk, M Frost, M Vinberg, EM Christensen, O Winther, JE Bardram, and LV Kessing. Translational Psychiatry, 2016. (ISSN: 2158-3188) (DOI: http://dx.doi.org/10.1038/ tp.2016.123), vol: 6, issue: 7, 2016

How electronic monitoring can assist a psychiatric medication change

How electronic monitoring can assist a psychiatric medication change

In undergoing psychiatric treatment for mental illnesses, it is very common to be prescribed medication. While medication can be an important and helpful part of treatment, the process of finding the right medication for each patient can be a tedious and sometimes hazardous process.  It is common practice for patients with mental illnesses, such as schizophrenia [1] , depression [2]  and bipolar [3], to switch through multiple psychiatric medications.

The Australian Genetics of Depression Survey, which includes 13,000 participants with clinical depression, reported that one in ten participants have used five or more antidepressants during their psychiatric treatment [2] The survey also reported that patients with depression will often cycle through multiple antidepressants using a trial and error approach to find the medication that best suits the patient. [2] However, by using the trial and error methodology, this process can take a very long before benefits are observed [2] and of more concern, patients may experience adverse health side effects from changing and stopping medication.

Adverse side-effects are an unfortunately common occurrence for patients taking psychiatric medication. The Australian Genetics of Depression Survey reported 76% of participants with clinical depression had some medication related side-effects and 38% of participants reported that side-effects of the medication were so severe that they had to either stop or change the medication. Participants in the survey reported antidepressant side-effects of nausea, headaches, drowsiness, and fatigue [2]. Other side-effects of antidepressants may include physical withdrawal pains from forgetting to take medication and ensuing anxiety over forgetting to take the medication again [4].

Adverse side-effects can also occur from abruptly stopping psychiatric medication. This can result in complications such as the rapid return of the illness being treated  [2], mild to moderate discontinuation symptoms[5], or in some severe cases, such as the cessation of a high dose of benzodiazepines, potentially life threatening seizures [5].

Fortunately, these side-effects can be reduced:

Firstly, it is strongly advised to take the medication switching or stopping process gradually, carefully, and slowly. [3] [5]

Secondly, harmful side-effects can be reduced for patients by maintaining constant engagement with their clinician through actively participating in their treatment by asking questions and providing feedback, closely monitoring their own behaviour and ensuring that their medication changes remain under active clinician supervision. [5]

Monitoring can be particularly critical to a medication switching period. According to Dr. Ross J. Baldessarini, the professor of psychiatry and neuroscience at Harvard Medical School and director of the psychopharmacology program at the McLean Division of Massachusetts General Hospital, the initial period following medication discontinuation is the most critical period and should be closely monitored, as some people may not experience the withdrawal and harmful symptoms of stopping medication for weeks, or even months after stopping the medication. [5]

Interactive electronic monitoring

An interactive electronic approach for self-monitoring offers a monitoring technique that includes a more accurate, comprehensive, and real-time assessment within naturalistic settings [6]. This type of monitoring is ideal for patients who are undergoing the medication switching process and need to constantly provide their clinician with accurate and extensive details about their mood states and behaviour.

There are several advantages to electronic monitoring as opposed to pen and paper data collection, such as:

  • Making data immediately available for analyses through online and digital formats [6]
  • By being able to log data in real time, patients are not subject to the same potential recall bias as when reporting data retrospectively using a pen and paper method. [7][8][9][10]
  • Daily information regarding patient behaviour that may have been lost due to cognitive dysfunction [6], impairments, stressful life or health factors, or simply forgetting, is readily recorded by an electronic system as opposed to depending on self-reporting with the pen and paper method.

Interactive Electronic Monitoring through Monsenso’s mHealth Solution 

Monsenso’s mHealth solution is an interactive electronic monitoring system which utilises a double loop feedback model. The first loop consists of the patient’s smartphone app and a web portal is connected to the second loop, which is the clinician’s web portal. The smartphone app uses sensors to automatically collect data from the patients, and allows patients to fill out a daily self-assessment regarding the state of their symptoms and their medicinal intake. This data is sent immediately to the connected clinician’s web portal.

Monsenso’s interactive electronic monitoring system can have these important benefits by optimising the consultation and engagement flow between patient and clinician:

  1. Offers the ability to verify the timing and compliance of data collection. [11]
  2. The smartphone app can send a daily notification with a reminder for the patient to complete the self-assessment or take their medication.
  3. Patients can fill out a customised diary note about the potential side-effects of medication or their symptoms to share with clinicians.
  4. Clinicians can obtain daily, real time, and comprehensive information about the clinical state of the patient, such as the state and occurrence of their symptoms and their medicinal intake.
  5. Patients and clinicians can obtain measures of daily variability of clinical states and behaviours of the patient.[11]
  6. This data is visualised in a line chart, where patients and clinicians can view the chart together to discover time-trends and relationships between behavioural variables and clinical states. [11]
  7. This information and awareness can foster patients to make earlier adjustments to their behaviour, as well as engage in a more focused treatment. [11]
  8. This information can also provide preparation for a clinician in administering rapid early intervention. [11]

The Monsenso mHealth solution can provide the carefully supervised and comprehensive monitoring of patients’ behaviour necessary to help ease the medication and stopping switching process.

[1] Effectiveness of switching antipsychotic medications. Susan M., et al. American Journal of Psychiatry 163.12.2090-2095. (2006)

[2] What Patients say about taking antidepressants. What patients say about taking antidepressants | 6 minutes. https://www.6minutes.com.au/node/20078

[3]  Getting Through a Major Medication Change. International Bipolar Foundation. http://www.ibpf.org/blog/getting-through-major-medication-change

[4]  My Impossible Quest for the Right Depression Meds.  I.Masad. Marie Claire. (2017, June 14) http://www.marieclaire.com/health-fitness/features/a20452/finding-the-right-depression-medication/ 

[5] Discontinuing Psychiatric Medications: What You Need to Know. M. Tartakovsky. Psych Central. (2016, July 17) https://psychcentral.com/lib/discontinuing-psychiatric-medications-what-you-need-to-know/

[6] Cognitive symptoms in patients with major depressive disorder and their implications for clinical practice. G. Papakostas. The Journal of clinical psychiatry 75.1 (2014):8-14.

[7] New technologies to improve clinical trials. Kobak, Kenneth A., et al. Journal of clinical psychopharmacology 21.3 (2001): 255-256.

[8] Patient compliance with paper and electronic diaries. Stone, Arthur A., et al. Controlled clinical trials 24.2 (2003): 182-199.

[9] The electronic assessment of the longitudinal course of bipolar disorder: the ChronoRecord software. Whybrow, P. C., et al Pharmacopsychiatry 36.S 3 (2003): 244-249.

[10] Trends in ambulatory self-report: the role of momentary experience in psychosomatic medicine. Conner, Tamlin S., and Lisa Feldman Barrett. Psychosomatic medicine 74.4 (2012): 327.

[11] Usability, Acceptability, and Adherence to an Electronic Self-Monitoring System in Patients With Major Depression Discharged From Inpatient Wards. Lauritsen, Lise, et al. Journal of medical Internet research 19.4 (2017).